CCCC
C4 Therapeutics Inc

2,472
Mkt Cap
$265.41M
Volume
1.86M
52W High
$3.82
52W Low
$1.09
PE Ratio
-2.00
CCCC Fundamentals
Price
$2.72
Prev Close
$2.75
Open
$2.78
50D MA
$2.29
Beta
1.94
Avg. Volume
1.88M
EPS (Annual)
-$1.27
P/B
1.03
Rev/Employee
$345,644.23
$30.23
Loading...
Loading...
News
all
press releases
C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab
C4 Therapeutics (NASDAQ:CCCC) outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays' 28th Annual Global Healthcare Conference, highlighting...
MarketBeat·19h ago
News Placeholder
More News
News Placeholder
C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference
C4 Therapeutics (NASDAQ:CCCC) used a presentation at TD Cowen's 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program...
MarketBeat·7d ago
News Placeholder
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·8d ago
News Placeholder
Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?
Here is how BrightSpring Health Services, Inc. (BTSG) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Zacks·9d ago
News Placeholder
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types PR Newswire VANCOUVER...
PR Newswire·9d ago
News Placeholder
C4 Therapeutics (NASDAQ:CCCC) Upgraded to Hold at Wall Street Zen
Wall Street Zen raised shares of C4 Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·14d ago
News Placeholder
C4 Therapeutics (NASDAQ:CCCC) Issues Earnings Results, Beats Expectations By $0.25 EPS
C4 Therapeutics (NASDAQ:CCCC - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by...
MarketBeat·16d ago
News Placeholder
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) has received an average rating of "Moderate Buy" from the eight ratings firms that are covering the company, MarketBeat Ratings reports. One...
MarketBeat·16d ago
News Placeholder
C4 Therapeutics (NASDAQ:CCCC) Stock Price Expected to Rise, Brookline Capital Acquisition Analyst Says
Brookline Capital Acquisition raised their price target on C4 Therapeutics from $20.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday...
MarketBeat·19d ago
News Placeholder
C4 Therapeutics (CCCC) Projected to Post Quarterly Earnings on Thursday
C4 Therapeutics (NASDAQ:CCCC) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·23d ago
<
1
2
...
>

Latest CCCC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.